G1 Therapeutics to Present at the Stifel Virtual Healthcare Conference on November 18, 2020

Rhea-AI Summary

G1 Therapeutics (GTHX) announces CEO Jack Bailey will present a company update at the Stifel 2020 Virtual Healthcare Conference on November 18, 2020, at 11:20 a.m. ET. Investors can access the live and archived webcast on the company's website.

G1 Therapeutics focuses on developing innovative cancer therapies, including trilaciclib, a treatment designed to enhance chemotherapy outcomes, and rintodestrant, a potential leading drug for ER+ breast cancer. The company has out-licensed rights for its oral CDK4/6 inhibitor, lerociclib.

RESEARCH TRIANGLE PARK, N.C., Nov. 11, 2020 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced that Chief Executive Officer Jack Bailey will present a company update at the Stifel 2020 Virtual Healthcare conference on November 18, 2020 at 11:20 a.m. ET.

To access the live and archived webcast of the presentation, please visit the Events & Presentations page of the G1 website.

About G1 Therapeutics
G1 Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development and delivery of next generation therapies that improve the lives of those affected by cancer. The company is developing and advancing two novel therapies: trilaciclib is a first-in-class therapy designed to improve outcomes for patients being treated with chemotherapy; rintodestrant is a potential best-in-class oral selective estrogen receptor degrader (SERD) for the treatment of ER+ breast cancer. In 2020, the company out-licensed global development and commercialization rights to its differentiated oral CDK4/6 inhibitor, lerociclib.

G1 Therapeutics is based in Research Triangle Park, N.C. For additional information, please visit www.g1therapeutics.com and follow us on Twitter @G1Therapeutics.

Contact:
Jeff Macdonald
G1 Therapeutics, Inc.
Senior Director, Investor Relations & Corporate Communications
919-907-1944
jmacdonald@g1therapeutics.com

FAQ

When will G1 Therapeutics present at the Stifel 2020 Virtual Healthcare Conference?

G1 Therapeutics will present on November 18, 2020, at 11:20 a.m. ET.

What is the focus of G1 Therapeutics?

G1 Therapeutics focuses on developing next-generation therapies for cancer treatment.

Who will represent G1 Therapeutics at the conference?

CEO Jack Bailey will present the company update at the conference.

How can I access the G1 Therapeutics presentation?

The presentation can be accessed live and archived on G1 Therapeutics' website.

What therapies are being developed by G1 Therapeutics?

G1 Therapeutics is developing trilaciclib and rintodestrant for cancer treatment.